Adam Mariotti, MD
Otolaryngology/Facial Plastic Surgery · Exton, PANPI 1184884298
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,446 of the $4,581 with a category attached, or 75.2%. 34 manufacturers reported payments, led by Sanofi at 31.3% of the total. Reporting peaked in 2024 at $1,669 and has fallen 54.6% since, to $757 in 2025.
Across 166 payments — averaging $27.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$1K
- GSK$612
- Regeneron Healthcare Solutions, Inc.$405
- Stryker$400
- Optinose US, Inc.$249
- Aerin Medical Inc.$156
- plus $1K from 28 others
What the payments were for
- Consulting fees$1,06023%
- Food & beverage$3,44675%
- Education$752%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 12 | $1,432 |
| GSK | 34 | $612 |
| Regeneron Healthcare Solutions, Inc. | 22 | $405 |
| Stryker | 13 | $400 |
| Optinose US, Inc. | 14 | $249 |
| Aerin Medical Inc. | 5 | $156 |
| Genentech USA, Inc. | 8 | $151 |
| Novartis | 9 | $133 |
| ARS Pharmaceuticals Operations, Inc. | 7 | $114 |
| Jazz Pharmaceuticals Inc. | 4 | $93 |
| AstraZeneca | 5 | $91 |
| Sanofi-aventis U.S. LLC | 1 | $75 |
| Neurent Medical Limited | 1 | $66 |
| Acclarent, Inc | 2 | $58 |
| Harmony Biosciences LLC | 2 | $57 |
| Kaleo, Inc. | 3 | $50 |
| Alk-abello, Inc | 3 | $47 |
| Vertex | 3 | $47 |
| Smith+Nephew | 1 | $34 |
| Intersect ENT, Inc. | 2 | $34 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Medtronic(2 entities) | 2 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Lilly USA, LLC | 1 | $23 |
| Eisai Inc. | 1 | $23 |
| Integra Lifesciences Corporation | 1 | $23 |
| Pfizer | 1 | $21 |
| Resmed Corp | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $20 |
| Phadia US Inc. | 1 | $19 |
| Aimmune Therapeutics, Inc. | 1 | $14 |
| Olympus America Inc. | 1 | $11 |
| Cook Medical LLC | 1 | $11 |
| Fortovia Therapeutics, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,581 in reported general payments places this provider in the 80th percentile of 21 otolaryngology/facial plastic surgery providers in Pennsylvania.
See all otolaryngology/facial plastic surgery providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Arnuity ElliptaFluticasone Furoate | 17 | $5,303 |
| Fluticasone Propionate | 225 | $4,542 |
| Ipratropium Bromide | 110 | $2,916 |
| Azelastine Hcl | 88 | $2,256 |
| Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort | 28 | $1,490 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 15 | $1,053 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $1,038 |
| Omeprazole | 97 | $997 |
| Methylprednisolone | 143 | $798 |
| Montelukast Sodium | 52 | $712 |
| Fluocinolone Acetonide Oil | 13 | $562 |
| Famotidine | 80 | $535 |
| Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid | 36 | $343 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 17 | $336 |
| Mometasone Furoate | 26 | $304 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKArnuity Ellipta | $612 | $5,30317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 21 otolaryngology/facial plastic surgery providers in Pennsylvania.
Other otolaryngology/facial plastic surgery in Exton
- Michael PicarielloExton$4K
- Jason BloomBryn Mawr$718K
- Donald SessoNorristown$23K
- Sean CarrollErie$6K
- Melissa SchwartzElkins Park$5K
- Jeffrey BrigliaLanghorne$4K
- Aykut UnsalPhiladelphia$4K
- Raphael GabayPhiladelphia$4K
- Jose UribeBethlehem$4K
- Harleen SethiPhiladelphia$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.